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A 78-year-old man on hemodialysis presented to our hospital with erythrocytosis. He
had started hemodialysis 4 years previously, with a hemoglobin level of 9.8 g/dL, and
was administered erythropoiesis stimulating agents and ferrous sulfate. Two years
previously, his hemoglobin level increased to 14.5 g/dL and the treatment for anemia
was discontinued. He continued hemodialysis thrice weekly; however, the hemoglobin
level had increased to 17.0 g/dL at the time of presenting to our hospital. His serum
erythropoietin level was 31.4 mIU/mL (range, 3.7–31.5 mIU/mL), carboxyhemoglobin
level was 0.6% (range, 0–1.5%), and oxygen saturation in ambient air was 95.4%. The
JAK2 V617F mutation was not observed and other bone marrow abnormalities were not
identiﬁed. The patient was diagnosed with bladder cancer and a transurethral resection
was performed. Eight months after the treatment of bladder cancer, his hemoglobin
level was 15.1 g/dL, and he was diagnosed with idiopathic erythrocytosis.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Erythrocytosis develops when the hemoglobin level
increases above the normal level (hematocrit,4 0.51 in males
and40.48 in females [1]). Erythrocytosis is classiﬁed as
relative (due to decreased plasma volume), primary (due to
an intrinsic defect of the erythropoietic component in the
bone marrow [1]), or secondary (associated with conditions
that increase erythropoietin levels) in origin. Secondary ery-
throcytosis can be caused by a physiological elevation due to
tissue hypoxia or an abnormal overproduction of erythropoie-
tin (i.e., patients with renal cysts, renal artery stenosis, and
tumors with ectopic erythropoietin production) [2]. Idiopathic
erythrocytosis is diagnosed when no causes for erythrocytosis
are identiﬁed. In the present report, we describe a case of an
end-stage renal disease (ESRD) patient who developed idio-




A 78-year-old man presented to our hospital with erythrocy-
tosis in November 2013. He was in a good condition while
continuing to receive hemodialysis thrice weekly for 4 years,
except for the presence of erythrocytosis, as per his monthly
blood tests. When he ﬁrst started hemodialysis, his hemoglobin
level was 9.8 g/dL, and therefore, ferrous sulfate and erythropoi-
esis stimulating agents were prescribed. Iron studies were
consistent with anemia of chronic disease (iron level, 100 μg/
dL; total iron binding capacity, 261 μg/dL; ferritin, 266 ng/mL).
However, the hemoglobin level had increased to 14.5 g/dL after
2 years, and therefore, treatment for anemia was discontinued.
After discontinuing anemia treatment, the hemoglobin level
increased to 17.0 g/dL despite the absence of any speciﬁc events
occurring to the patient (Fig. 1). He was diagnosed with hyper-
tension 10 years previously, gout 8 years previously, and had
started chronic hemodialysis 4 years previously. A computed
tomography (CT) scan was performed 4 years previously because
he was found to have renal stones during radiography. CT
indicated the presence of multiple renal stones and dilatedhrology. Published by Elsevier. This is an open access article under the
Figure 1. Patient’s hemoglobin levels. The X-axis denotes the time course since the start of hemodialysis and the Y-axis denotes the serum
hemoglobin level (g/dL). Bars with text represent the duration for which erythropoiesis stimulating agents and ferrous sulfate were prescribed. The
patient started hemodialysis in April 2010, with the administration of erythropoiesis stimulating agents and ferrous sulfate. In April 2012, the serum
hemoglobin level in the patient was 14.1 g/dL and treatment with erythropoiesis stimulating agents and ferrous sulfate was discontinued. Despite
discontinuing anemia treatment, the serum hemoglobin level gradually increased to 18.1 g/dL. In December 2013, an operation was performed for
bladder cancer, and the serum hemoglobin level decreased to 14.6 g/dL in April 2014. However, the hemoglobin level again increased to 15.1 g/dL in
August 2014.
Figure 2. The patient’s computed tomographic (CT) and cystoscopic images. (A) The patient’s CT image in February 2010. Multiple renal
parenchymal and renal pelvic stones with dilated calyces in both kidneys and hydronephrosis in the left kidney are shown. (B) The patient’s CT image
in November 2013. Multiple renal stones in the left kidney and dilated calyces and hydronephrosis are shown. The dilated calyces and hydronephrosis
had not worsened compared with the CT image obtained in February 2010. (C) The patient’s CT image in November 2013. A nodular lesion in the right
anterior aspect of the urinary bladder is shown. (D) The patient’s cystoscopic image. A solitary mass lesion on the right anterior wall of the urinary
bladder is shown.
Lee et al / Erythrocytosis in ESRD 61
Kidney Res Clin Pract 34 (2015) 60–6362calyces in both kidneys and hydronephrosis in the left kidney.
(Fig. 2A).
When the patient presented to our hospital in 2013, he was
stable with a blood pressure of 130/80 mmHg and a pulse rate
of 88 beats/min. The patient had a height of 162 cm, weight of
66 kg, and a body mass index of 25.1 kg/m2. He had been living
at an altitude of 50 m above sea level. He had no complaints
of headache, visual disturbances, vertigo, paresthesia, fatigue,
and chest or abdominal pain. His only complaint was painless
gross hematuria. According to his family, he did not snore or
have any apneic periods during sleep. He had a history of
smoking (65 pack-year), but stopped 4 years previously. There
was no history of cardiopulmonary disease and transfusion of
blood products. We referred the patient to a urologist due to
his CT ﬁndings, but the urologist did not treat the patient because
the related symptoms were not present. The patient did not have
a familial history of erythrocytosis. His medication included:
pyridoxine 10mg; thiamine 1.5 mg; riboﬂavin 1.7 mg; ascorbic
acid 60mg; folic acid 1 mg; cyanocobalamin 6 μg; aspirin 100mg;
lercanidipine 20mg; ezetimibe 10 mg; simvastatin 10 mg; dox-
azosin 8 mg; allopurinol 100 mg; and tianeptine 12.5 mg daily. He
was not taking androgens or anabolic steroids.
The following ﬁndings were observed during the evaluation
when the patient visited us: white blood cell count, 7,520/μL;
hemoglobin, 18.9 g/dL; hematocrit, 53.5%; platelet count,
145,000/μL; blood urea nitrogen, 26.7 mg/dL; creatinine,
6.7 mg/dL; protein, 7.5 g/dL; albumin, 4.4 g/dL; aspartate
transaminase/alanine transaminase, 22/24 IU/L; uric acid,
5.3 mg/dL; calcium, 10.1 mg/dL; and phosphorus, 3.1 mg/dL.
Hepatosplenomegaly was not observed. According to the
peripheral blood smear, there were no other defects, except
for normochromic macrocytic red blood cells. The patient’s
serum erythropoietin level was 31.4 mIU/mL (range, 3.7–
31.5 mIU/mL). Arterial blood gas analysis revealed the follow-
ing: pH, 7.46; PaCO2, 37.9; PaO2, 75.6; HCO3, 26.7; and O2
saturation in ambient air, 95.4%. The serum carboxyhemoglo-
bin level was 0.6% (range, 0–1.5%). Serum tumor marker levels
were normal (CEA, 2.64 ng/mL; AFP, 2.38 ng/mL; PSA, 2.04 ng/
mL). After bone marrow aspiration and biopsy of the patient,
we observed a slight increase in erythroid elements with aFigure 3. Patient’s DNA sequencing test for the JAK2 V617F muta-
tion. A substitution of guanine (G) by thymine (T) at the nucleotide
position 1849 [c.1849G4 T (V617F) mutation] within exon 14 of the
JAK2 gene was not identiﬁed.megaloblastoid appearance of some late normoblasts. The
V617F mutation of the JAK2 gene was absent (Fig. 3).
The chest radiograph did not reveal cardiomegaly or any
parenchymal abnormalities. The following values were
obtained from the pulmonary function test: FEV1/FVC, 71%;
FVC, 101%; and FEV1, 104%. In the echocardiographic image, the
right to left shunt was not observed, and the systolic and
diastolic functions were normal. A gastric ulcer was observed
with esophagogastroduodenoscopy, and no abnormal lesions
were observed with colonoﬁberscopy. In the abdominopelvic
CT image, we observed no interval change in both renal stones
and a decrease in the size of the dilated calyces of left kidney
compared with the images obtained 4 years previously
(Fig. 2B). Therewas no evidence of renal cysts, renal cell carcinoma
(RCC), or hepatocellular carcinoma (HCC) in the CT image.
A nodular lesion suspicious for bladder cancer was detected in
the bladder and the patient underwent a transurethral resection of
the bladder in December 2013. The nodular lesion was subse-
quently diagnosed as transitional cell carcinoma (Fig. 2C and D).
After the treatment of bladder cancer, the hemoglobin level
decreased gradually to 14.6 g/dL 4 months after the operation,
and bladder cancer was considered as the cause of erythrocytosis.
However, the hemoglobin level increased again to 17.2 g/dL
5 months after the operation and to 15.1 g/dL after 8 months.
After excluding the possible causes of erythrocytosis, we diag-
nosed the patient with idiopathic erythrocytosis, and the patient is
currently being monitored closely.Discussion
Some of the reported causes of erythrocytosis in hemodialysis
patients include polycythemia vera, gastric cancer, RCC, acquired
cystic kidney disease, and obstructive sleep apnea syndrome [3–7].
Acquired renal cystic disease is a frequently reported cause of
secondary erythrocytosis in hemodialysis patients. The main
mechanism of elevation in the serum erythropoietin levels in
patients with acquired renal cystic disease involves the overpro-
duction of erythropoietin by the epithelial lining of renal cysts [8].
Several investigators have previously reported on cases of
erythrocytosis caused by hydronephrosis, regardless of the
hemodialysis state. The mechanism involves increased medul-
lary hypoxia caused by increased pressure of the renal pelvis
on the medullary vasculature [9]. In the present case, left-
sided hydronephrosis was already present 4 years previously;
however, erythrocytosis was not present at that time, and we
predicted that decreased kidney function may have been a
contributing factor in such cases.
Another cause of excessive erythropoietin production is the
presence of erythropoietin-producing tumors. Erythropoietin-
producing tumors such as RCC and HCC are frequently
encountered in ESRD patients [10]. Therefore, malignancies
should also be considered as a cause of erythrocytosis in
chronic hemodialysis patients.
Another suspected factor for erythrocytosis in our patient
was bladder cancer. However, the erythropoietin-producing
property of bladder cancer has not yet been established. At
present, there is only a single report of spontaneous erythro-
cytosis proven to be caused by bladder cancer in a patient with
normal renal function [11]. However, the bladder cancer in the
present case was not found to be the cause of erythrocytosis
because the serum hemoglobin levels again increased after the
operation for tumor removal.
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erythropoietin receptor gene [i.e., a deletion mutation
(Del1377-1411), nonsense mutation (C1370A), and missense
mutation (G1445A)], or mutations in the erythropoietin-
receptor signaling system (JAK2 mutation) [12]. We searched
for JAK2 mutation, but mutations of the erythropoietin recep-
tor gene were not tested. We suggest that mutations of the
erythropoietin receptor gene should also be considered as a
cause of erythrocytosis.
Sheqwara et al [8] reported occurrence of idiopathic ery-
throcytosis in a hemodialysis patient. The differences from our
patient were as follows. The patient was a 68-year-old man with
a history of diabetes mellitus who did not use erythropoietin-
stimulating agents or iron supplements. The time to identiﬁcation
of erythrocytosis was shorter (22 months) in their patient than in
our patient (55 months). Furthermore, there were no radiologic
evidences for hydronephrosis or malignancy. However, the
reported patient’s erythropoietin level was 49.45 mU/mL (range,
3.7–31.5 mU/mL). We believe that they should have searched for
possible causes of elevated erythropoietin level, such as sleep
apnea syndrome.
In the present case, the serum erythropoietin level was
31.4 mIU/mL. Given the high serum hemoglobin levels, we can
interpret that the serum erythropoietin level in our patient was
relatively raised; the serum erythropoietin level would otherwise
have been near the lower normal limit because of the negative
feedback mechanism. However, Artunc and Risler [13] reported
that the correlation between hemoglobin and serum erythropoie-
tin concentrations was absent in chronic kidney diseases stages
4 and 5. Based on this ﬁnding, we can expect that the serum
erythropoietin level in the present case would not be relatively
elevated. Therefore, it would be more reasonable to assume that
the cause of erythrocytosis in ESRD patients with erythrocytosis
and normal erythropoietin levels is not secondary erythrocytosis.
Hence, further studies are required to evaluate the relationship
between erythrocytosis and erythropoietin levels and the causes
for erythrocytosis in ESRD patients.Conﬂict of interest
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